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Sclerosing encapsulating peritonitis (SEP) is a rare but
serious complication in patients with continuous ambulatory
peritoneal dialysis (CAPD), and is characterized by a progres-
sive, intra-abdominal, inflammatory process resulting in the
formation of sheets of new fibrous tissue, which cover, bind,
and constrict the viscera, thereby compromising the motility
of the bowel. No satisfactory estimate is available on the com-
parative incidence of dialysis related SEP and the pathogenesis
of SEP still remains uncertain. Although recent therapeutic
approaches have reported varying degrees of success, an effi-
cient measure to detect, at an early stage, patients at risk for
SEP would be beneficial and a standardized treatment regimen
to prevent the illness is urgently needed. This study aimed to
evaluate the clinical features of SEP and to identify the pos-
sible risk factors for the development of SEP in CAPD
patients. We retrospectively reviewed by questionnaire SEP
cases among CAPD patients from 7 university hospital dialysis
centers in Korea, including Yonsei University, Ajou Uni-
versity, Catholic University, Inha University, Kyungpook Uni-
versity, Seoul National University and Soonchunhyang Uni-
versity, from January 1981 to December 2002. Out of a total
of 4,290 CAPD patients in these centers, 34 cases developed
SEP with an overall prevalence of 0.79%. The male to female
ratio was 17:17. The median age of these patients was 44.5
years (range 19 - 66). The median duration of CAPD before
SEP was 64 months (9 - 144) and 68% of patients (23/34) had
been on CAPD for more than 4 years. Peritonitis (including
two fungal cases) was the main cause of catheter removal in
SEP (27 cases, 79%). Seventy-five percent of the cases (15/
20) were administered -blocker for a mean duration of 85β
months (26 - 130). Among 10 cases with available peritoneal
equilibration test (PET) data, 8 showed high transporter char-
acteristics, and the remaining 2 were high average. Eighteen
cases were diagnosed by clinical and radiologic methods, and
16 were surgically diagnosed. Eleven cases were surgically
treated and the others were treated conservatively with inter-
mittent total parenteral nutrition (TPN). The overall mortality
rate was 24%. SEP is a serious, life threatening complication
of CAPD. Most cases had a PD duration of more than 4 years,
a history of severe peritonitis, and high transporter charac-
teristics in PET. Therefore, to reduce the incidence of SEP,
careful monitoring and treatment, including early catheter
removal in patients with severe peritonitis, should be con-
sidered for long-term CAPD patients with the above charac-
teristics.
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INTRODUCTION
Sclerosing encapsulating peritonitis (SEP) was
first described by Gandhi et al.,
1
and is a rare but
serious complication of peritoneal dialysis (PD),
which remains a life threatening condition in PD
patients. Due to the rarity and the relatively long
development period, there is no satisfactory esti-
mate of the comparative incidence of dialysis
related SEP.
2
Early diagnosis and treatment prior
to the development of symptoms is difficult. Al-
though it is important to detect patients with an
increased risk of developing SEP, there is no
known clinical predictor for SEP.3,4 Clinical features
are variable and include, abdominal pain, nausea,
vomiting, weight loss, loss of ultrafiltration, as-
cites, and blood stained dialysate.5 The diagnosis
of disease is usually made at laparotomy, but
recently findings on CT scans and ultrasounds of
the peritoneum have been used to support diag-
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The purpose of this study was to evaluate the
clinical characteristics of SEP patients and to iden-
tify clinical features associated with SEP in con-
tinuous ambulatory peritoneal dialysis (CAPD)
patients. The peritoneal equilibration test (PET),
which may herald the occurrence of SEP was
conducted on these patients, and some clinical
parameters suspected to be related with SEP were
determined.
MATERIALS AND METHODS
This study was a retrospective multi-center
study that reviewed SEP patients in 7 university
hospital dialysis centers in Korea.
Patient selection
A questionnaire review was conducted on 4,290
CAPD patients from 7 University hospital dialysis
centers in Korea, including Yonsei University,
Ajou University, Catholic University, Inha Univer-
sity, Kyungpook University, Seoul National Uni-
versity, and Soonchunhyang University, from
January 1981 to December 2002.
Patients were included if the following two
criteria were satisfied; Firstly, surgical or radio-
logic evidence of SEP, such as, dilated fixed loops
matted together and tethered posteriorly, ad-
herent dilated bowel loops, loculated ascites, or
small-bowel obstruction with thickened periton-
eum in the absence of other causes of bowel
obstruction. Secondly, CAPD duration was greater
than 3 months before the onset of SEP.
Clinical characteristics
Clinical data on SEP patients was obtained ret-
rospectively by chart review in each hospital.
Information was obtained regarding the number
of cases, age, gender, duration of continuous peri-
toneal dialysis prior to diagnosis (< 3 month inter-
ruption), underlying causes of end-stage renal
disease (ESRD), beta blocker usage, interval
between PD catheter removal and the diagnosis of
SEP and causes of PD catheter removal.
Clinical features of SEP, such as, the number of
events of peritonitis and the cumulative duration
of peritonitis treatment (total duration of anti-
biotics usage) before the diagnosis of SEP, causa-
tive organisms of peritonitis, ascites after PD
catheter removal, nutritional status, and peritoneal
transport characteristics were also analyzed.
Nutritional status was classified into three groups
according to mean serum albumin level over the
first 3 months after the diagnosis of SEP (Good:
albumin 3.0g/dL, Intermediate: 3.0g/dL al-
bumin < 3.5g/dL, Poor: albumin < 3.0g/dL).
Finally, treatment and outcome were evaluated.
Treatment duration of SEP was defined as the
total reported treatment time (Hemodialysis, total
parenteral nutrition, steroid) until a patient be-
came symptom free or expired.
Peritoneal transport characteristics
In patients who were given PET, CAPD was
performed using commercially available dialysis
solution, which contained lactate as a buffer. The
last PET results before the onset of SEP were
analyzed in this study. Patients used 2-L bags four
times a day. The glucose concentration was de-
pendent on the amount of fluid that had been
removed.
Peritoneal permeability studies were performed
in the absence of peritonitis, using a dialysate
volume of 2-L, glucose concentration of 2.5%, and
a dwell time of four hours.7,8 After the completion
of infusion (0 time) and at 120 minutes dwell time,
200 mL of dialysate was drained. A 10 mL sample
was taken and the remaining 190 mL was infused
back into the peritoneal cavity. A serum sample
was obtained at 120 minutes. At the end of the
dwell (240 minutes), the dialysate was drained in
the upright position (drain time not to exceed 20
minutes). The drain volume is measured and a 10
mL sample was taken from the drain. All the sam-
ples were sent for solute measurement (creatinine,
urea, and glucose). Serum and dialysate creatinine
concentrations were corrected for a high glucose
level, which contributes to non-creatinine chromo-
gens during the creatinine assay. The Dt/D0 glu-
cose and the D/P ratios for creatinine, urea, and
others were calculated.
A total of 10 PET available cases were analyzed
to investigate peritoneal membrane permeability
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characteristics.
Statistical analysis
All values are expressed as median values with
a distribution range. Statistical analysis was per-
formed using the statistical package SPSS for
Windows Version 11.0 (SPSS, Inc., Chicago, IL,
USA). Results were analyzed using the Kruskal-
Wallis one-way test and the Mann-Whitney U test.
A p-value of less than 0.05 was considered statisti-
cally significant.
RESULTS
Out of the total of 4,290 CAPD patients ad-
mitted between Jan. 1981 and Dec. 2002 in the 7
centers, 34 cases developed SEP with an overall
prevalence of 0.79%. The prevalence rates at the
individual dialysis centers were 0.58% (12/2,078)
in Yonsei for 21 years, 0.28% (2/719) in Kyung-
pook for 16, 2.86% (14/490) in Soonchunhyang for
9, 0.32% (1/312) in Ajou for 8 years, 1.16% (2/172)
in Seoul National for 16, 0.87% (2/230) in Catholic
for 7, and 0.35% (1/289) in Inha for 6 (Table 1).
Table 2 presents the demographic data of the SEP
patients. The male to female ratio was 17:17 and
median patient age was 44.5 years (range 19.0 -
66.0). The median duration of CAPD before cathe-
ter removal was 64.0 months (range 9.0 - 144.0)
and 68% of patients (23/34) had been on CAPD
for more than 4 years (Fig. 1). Seventy-five percent
of the cases (15/20) used -blocker for a meanβ
duration of 85.0 months (range 26.0 - 130.0). The
median interval between PD catheter removal and
Table 2. Demographic Data of SEP Patients
Male : Female 17 : 17
Age (yrs) 44.5 (19.0-66.0)
Number of patients using -blockerβ 15/20 (75%)
Duration of -blocker usage (months)β 85.0 (26-130.0)
Interval between CAPD catheter removal and diagnosis of SEP (months) 4.0 (1.0-30.0)
Number of peritonitis before the diagnosis of SEP 6.0 (0-15.0)
Cumulative duration of peritonitis (weeks) 12.0 (0-84.0)
Note, Data are expressed as median (range).
SEP, sclerosing encapsulating peritonitis; CAPD, continuous ambulatory peritoneal dialysis.
Table 1. Prevalence of SEP in 7 Dialysis Center in Korea
University Observation Period (yrs) No. of SEP CAPD Cases Prevalence (%)
Yonsei 21 12 2078 0.58
Ajou 8 1 312 0.32
Catholic 7 2 230 0.87
Inha 6 1 289 0.35
Kyungpook 16 2 719 0.28
Seoul National 16 2 172 1.16
Soonchunhyang 9 14 490 2.86
Total 34 4290 0.79
SEP, sclerosing encapsulating peritonitis; CAPD, continuous ambulatory peritoneal dialysis
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a diagnosis of SEP was 4.0 months (range 1.0 -
30.0).
Peritonitis was the main cause of catheter re-
moval in SEP (27 cases, 79%), followed by ultrafil-
tration failure (5 cases, 15%), and one case each of
dialysate leak and exit site infection. The median
number of peritonitis events before a diagnosis of
SEP was 6 (range 0 - 15) and the cumulative dura-
tion of peritonitis was 12.0 weeks (range 0.0 - 84.0).
The causative organisms of peritonitis prior to PD
catheter removal were methicillin-sensitive Stap-
hylococcus epidermidis (MSSE, 9 cases, 32%), meth-
icillin-sensitive Staphylococcus aureus (MSSA, 7
cases, 25%), Candida species (2 cases, 7%), others
(4 cases, 14%), and no growth (6 cases, 21%).
Eighteen cases were diagnosed by clinical and
radiologic methods, and 16 cases were surgically
diagnosed. The presenting signs and symptoms
before a diagnosis of SEP were often gastrointesti-
nal and abdominal pain (10/20, 50%), nausea and
vomiting (11/20, 55%) and poor oral intake (4/20,
20%). Thirteen cases showed persistent ascites
after catheter removal (37%). Their nutritional sta-
tuses after a diagnosis of SEP were poor in 11
cases (32%), intermediate in 15 (44%), and good in
8 (23%). Among 10 cases with available PET data,
8 showed high transporter characteristics and the
remaining 2 were high average (Table 3).
Median treatment duration after a diagnosis of
SEP was 3.5 months (range 1 - 27). Treatment mo-
dalities were hemodialysis only (HD, 16 cases,
46%), HD with total parenteral nutrition (TPN, 6
cases, 17%), HD with surgery (OP, 11 cases, 31%),
and HD with steroid (PL, 2 cases, 6%). In surgi-
cally treated cases, laparotomies with/without
surgical excision of the sclerosed peritoneum were
performed. The overall mortality rate was 24%.
Eight patients died at an average of 5.3 ± 5.9
months after SEP diagnosis. The mortality showed
a higher rate in patients with surgical treatment
(4/11, 43%) than in the other treatment groups
(Table 4), but this was not statistically significant.
DISCUSSION
Sclerosing encapsulating peritonitis (SEP) is a
rare but serious complication in patients rece-
iving continuous ambulatory peritoneal dialysis
(CAPD). SEP, first described by Gandhi et al.
1
in
1980, usually occurs in patients who have been
on peritoneal dialysis for many years, but some-
times it occurs much earlier.3 The utilization of
the peritoneal cavity for dialysis introduces the
risk of structural or functional damage to the
peritoneal membrane. Small bowel obstruction
due to encapsulation, dense adhesions, and mu-
ral fibrosis are characteristic and are often asso-
ciated with peritonitis.
2
This disorder is consid-
ered to constitute peritoneal sclerosing syndrome
with variable clinical features.1-3,9,10
The incidence and prevalence of this syndrome
have been defined in some large populations and
by a few single-center experiences, but due to the
Fig. 1. Distribution of sclerosing encap-
sulating peritonitis (SEP) cases according
to CAPD duration (N=34). SEP was com-
monly noted in the patients with CAPD
duration of more than 4 years.
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low incidence and the relatively long develop-
ment, there is no satisfactory estimate of the com-
parative incidence of dialysis related SEP2. In our
study, 34 cases of SEP were diagnosed with a
prevalence rate of 0.79%. This prevalence rate is
similar to that of Japan, Australia, and Canada
with 0.9% (62/6, 923) reported by Nomoto Y et
al.,10 0.7% (54/7, 374) by Rigby RJ and Hawley
CM,11 and 0.54% (7/1, 288) by Afthentopoulos IE
et al.,12 respectively.
The underlying diseases of ESRD in cases with
SEP were most commonly chronic glomerulone-
phritis (48%), followed by hypertension (19%). No
patients with diabetes were found even though
diabetes mellitus (DM) is the most common cause
of ESRD in Korea. This may be partly because
technical survival of CAPD patients with DM is
much shorter than that of other patient popula-
tions. Thereby, they might have been withdrawn
from CAPD before the clinical onset of SEP.
However, other reasons are also possible.
Although various kinds of causative factors
have been reported, there is no known single etio-
logic factor directly related to SEP.
3,4
This is pro-
bably because the frequency of the disorder is low
and the time needed to develop of clinical disease
Table 4. Mortality Rate According to Treatment Modality
Treatment Modality No. of Cases Survival : Death Mortality Rate (%)*
Hemodialysis only 14 12 : 2 14
Total parenteral nutrition 7 5 : 2 29
Surgery 11 7 : 4 43
Steroids 2 2 : 0 0
Total 34 26 : 8 24
*Mortality rate did not show statistical significance.
Table 3. Clinical Characteristics of SEP
Diagnostic method (clinical and radiologic : surgical) 18 : 16
Presenting symptoms (n=20)
Abdominal pain 10/20 (50%)
Nausea/Vomiting 11/20 (55%)
Poor oral intake 4/20 (20%)
Number of cases with persistent ascites after removal of CAPD catheter 13/34 (37%)
Nutritional status after diagnosis of SEP
Good (serum albumin 3.0 g/dL) 8 (23%)
Intermediate (3.0 g/dL serum albumin<3.5 g/dL) 15 (44%)
Poor (serum albumin<3.0 g/dL) 11 (32%)
PET result (n=10)
High 8
High average 2
Median treatment duration after diagnosis of SEP (months) 3.5 (1.0-27.0)
SEP, sclerosing encapsulating peritonitis; CAPD, continuous ambulatory peritoneal dialysis.
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is protracted.
In terms of the causes of SEP, PD dependent
risk factors and PD independent risk factors may
be involved,13 such as, PD duration, poor biocom-
patibility (due to acetate, disinfectant), and peri-
tonitis could be important in the development of
SEP,2,5,12,14-19 -blockers, and a genetic preβ dispo-
sition have also been mentioned as independent
factors.20-22
Of the various etiologic risk factors, peritonitis
is the most common cause of SEP, and in parti-
cular, Staphylococcus aureus, fungi, pseudomonas
species, and Hemophilus influenzae are more
likely to develop SEP.2,5,11,12,14,16-19,23-26 Loss of
mesothelium during peritonitis causes damage to
the peritoneal membrane due to bioincompati-
bilities with substances in PD solutions. Moreover,
the loss of fibrinolytic capacity of the peritoneal
membrane could contribute to the development of
SEP following severe peritonitis.27-29 Antibiotics
used in peritonitis, such as, vancomycin and
amphotericin B, could also be risk factors of SEP.
14,30,31 Peritonitis was the most common cause of
PD catheter removal involving 79% of cases in our
study. Even though we could not show a direct
relationship between peritonitis and the occur-
rence of SEP, it is likely that peritonitis makes
some contribution to its development.
The duration of CAPD is an important determi-
nant factor for SEP. SEP usually occurs in patients
receiving CAPD for more than 4 or 5 years, as
shown by our data. Rigby RJ and Hawley CM
12
in Australia also emphasized the impact of CAPD
duration on the development of SEP. They re-
ported a low SEP frequency in patients on peri-
toneal dialysis for less than 2 years, with a preval-
ence rate of 1.9%, rising to 6.4, 10.8, and 19.4% in
patients on peritoneal dialysis for greater than,5,6
and 8 years, respectively.
14
This suggests that non-
physiologic dialysis solutions may induce a chronic
sterile inflammation in the peritoneal cavity,
thereby inducing several cytokines, which accel-
erate collagen synthesis by mesothelial cells and
fibroblasts. Moreover, the high glucose, high
lactate, and low pH in the dialysate can be perni-
cious to the peritoneal membrane.
Beta-blockers such as practolol or atenolol are
known to cause SEP.2,20,21 Practolol is the most
commonly implicated -blocker in the pathoβ -
genesis of SEP, and metoprolol, propranolol, and
atenolol may also be linked to SEP.20-22 Beta-blo-
ckers may inhibit surfactant release and cause
damage to various serous membranes in the
body.2 We also found that many patients with
SEP had a history of -blocker usage. However,β
the clinical significance of this drug on the devel-
opment of SEP was not clarified by in the current
study.
Early diagnosis prior to the development of
symptoms is difficult6. Patients with SEP can de-
velop gastrointestinal symptoms such as anorexia,
nausea, and vomiting due to intestinal obstruc-
tion. A loss of dialysis efficiency can also develop.
Ascites is an important diagnostic clue to the
development of SEP after the suspension of PD.32
In our study, many SEP cases had gastrointestinal
symptoms and developed ascites. Symptoms re-
lated to SEP are known to be caused by pathologic
interference with intestinal function and perito-
neal integrity.13 The encapsulating process is re-
sponsible for disturbances in intestinal functions
that are manifested as disorders of gastrointestinal
motility with resultant impairment of reabsorptive
disorders, which finally result in protein and calo-
rie malnutrition.
In cases with SEP, an increase in the mass trans-
fer area coefficient of creatinine leads to a pro-
gressive loss of ultrafiltration, and decreased
CA-125 levels in dialysis fluid were noted due to
the loss of mesothelial cells.19,33 Of 10 cases where
PET data were analyzed,8 showed high trans-
porter characteristics and the remaining 2 were
high averages. The early detection of SEP may be
possible if peritoneal solute and fluid kinetics are
monitored regularly.
There is no agreement on whether the treatment
of choice is surgical, or conservative therapy, con-
sisting of transfer to HD with/without TPN and
immunosuppressive drugs including steroids.12
14,30,34-39
Regarding the low frequency of the
disease, these treatments have been limited to case
reports or small series. The duration of SEP
treatment in our study was similar to that of other
reports. Twenty-three of 34 patients were treated
conservatively and 11 were treated surgically. The
mortality of these SEP patients, at 24%, was com-
parable with that of other reports. The key
strategies of conservative treatment are early SEP
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detection, the cessation of CAPD with transfer to
HD, and sustained bowel resting with TPN. Surgi-
cal treatment is usually reserved for intestinal
obstruction.11,14,16,18,19 Extremely high mortality
rates of 60% are due to postoperative complica-
tions, typically the opening of an intestinal anas-
tomosis. Our study also showed highest mortality
in the surgically treated group, although this was
not statistically significant. The reason for this is
unclear, but disease severity in this group may
have been more severe than in the other groups
or the postoperative complications of SEP were
frequent, as found by the above studies.
This study has some limitations. First, because
it was a retrospective study performed by written
questionnaire, the actual prevalence of SEP may
have been underestimated because some SEP
cases might have been missed due to the unclear
diagnostic criteria for SEP. Second, because the
number of cases was small, it is difficult to
generalize on the characteristics of SEP from the
results of our study. Therefore, a larger scale,
controlled analysis of the clinical features of SEP
is required.
In conclusion, SEP is a rare but serious compli-
cation in patients with CAPD. Early PD catheter
removal with careful monitoring and treatment
should be seriously considered for patients with
long-term CAPD exceeding 4 years who experi-
ence complications with severe peritonitis, to
avoid severe peritoneal damage and the develop-
ment of SEP.
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